triple negative breast cancer life expectancy – You will surely find out and get to know breast cancer. Breast cancer is a malignant tumor. Breast cancer occurs when cells become abnormal and split breast without control or order.
Normal cells are divided and are produced on the basis of the order. Sometimes the process sequence is interrupted and the cells grew and divided outside the control of producing extra tissue that forms during or lumps called tumors.
Tumors can be benign (non-cancerous) or malignant (cancer). Breasts are mostly made of fat cells and gland cells. Glands in the breast milk production is made of individual cells normally reproduce under the control of hormones.
Sometimes this uncontrolled reproduction process and abnormal gland structures are formed. This became the beginning of cancer. The majority of breast cancer started from the funnel of the milk. A small percentage ranging from milk sacs or lobulus.
But did you know about breast cancer-triple negative? What sets it apart from the breast cancer that we know?
Detail about life expectancy triple negative metastatic breast cancer
What is Triple Negative breast cancer?
Triple-negative breast cancer is breast cancer sub-types that are clinically negative for expression of estrogen and progesterone receptor (ER/PR) and the protein HER2.
For it is important for us to understand the receptor, which is a protein found inside and on the surface of the cell receptor Proteins. This is the “eyes” and “ears” of the cell, receive messages from substances in the blood stream and then tell what cells It should be done.
It is characterized by a unique molecular profile, aggressive behavior, and patterns of metastasis. Although not identical, the vast majority of triple negative breast cancer carry a basic molecular profile on the order of gene expression.
This type of cancer and tend to be more aggressive than other types of breast cancer. Research has shown that the triple negative breast cancer are more likely to spread beyond the breast and more likely to recur (come back) after treatment.
This risk appears to be greatest in the first few years after treatment. For example, a study of more than 1,600 women in Canada, published in 2007 found that women with triple-negative breast cancer are at risk of getting cancer is higher in other parts of the body other than the breast but only for 3 the first year.
Other studies have reached the same conclusion. As time goes by, the risk of triple-negative breast cancer recurring became similar to the level of risk for other types of breast cancer.
About 10-20% of breast cancer was found to have the type of triple-negative. For doctors and researchers, there is a strong interest to find new drugs that can treat breast cancer of this kind.
This cancer also have a higher level than other types of breast cancer. The higher the level, the less the cancer cells resemble normal. On a scale of 1 to 3, triple-negative breast cancer often is class 3.
Research and treatment
Many kinds of treatment for this cancer, such as surgery, radiation therapy, and chemotherapy. However, many women worry when they learn that additional treatments, such as hormonal therapy and Herceptin are not likely to treat breast cancer-triple negative.
Some research has shown that breast cancer with hormone-receptor-negative or triple-negative breast cancer, actually respond to chemotherapy better than breast cancer that is hormone-receptor-positive.
If a cancer survivors follow the care plan makes the most sense for their specific situation, while doing its best to make healthy lifestyle choices, like eating a healthy low-fat foods, exercising regularly, and limit alcohol, then the sufferer has done all that he could to treat cancer.
But new research is being studied, and there is encouraging news about chemotherapy for triple-negative breast cancer.
Offered from Medical News Today, Friday (16/3), a new study from the University of Freiburg in Germany was testing the possibility of new avenues for the treatment of this type of cancer.
Dr. Jochen Maurer, of Translational Cell Research Center, and Dr. Roland Schüle, of the Center for clinical research, both based at the University of Freiburg research breakthroughs around similar stem cells of cancer, which encourages early tumor growth This cancer.
If advanced research scientists continue to bring successful results, this will be a good sign for the future treatment of triple-negative breast cancer, which currently has a poor long-term outcomes.